Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis announced a breakthrough in gene therapy for Sickle Cell Disease (SCD) using a non-viral approach published in Nature Communications. The therapy employs TALEN® technology for precise HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). This method achieves over 50% expression of normal hemoglobin in treated cells, effectively correcting the sickle cell phenotype without adverse effects. The preclinical data shows promising therapeutic potential and efficient engraftment in animal models, indicating readiness for clinical application. This innovative approach offers hope for addressing SCD and other genetic diseases.
- Cellectis developed a non-viral gene therapy for Sickle Cell Disease using TALEN® technology.
- The gene correction achieved over 50% expression of normal hemoglobin in treated cells.
- The therapy demonstrated precision and minimal genomic adverse events.
- Preclinical data showed efficient engraftment in animal models.
- The technology offers a new alternative treatment for SCD patients, especially those with options.
- The announcement lacks information on clinical trial timelines or regulatory approval status.
- Potential risks or long-term safety concerns of the non-viral approach are not addressed.
- No financial data or impact on Cellectis's revenue and profitability provided.
Insights
The unveiling of a non-viral gene therapy approach for sickle cell disease (SCD) marks a significant milestone in the field of genetic medicine. The approach, outlined in Nature Communications, utilizes TALEN® technology and non-viral gene repair templates to correct the HBB gene mutation responsible for SCD. This strategy shows high precision and specificity, with minimal genomic adverse events, which could translate into safer therapeutic options for patients.
The achievement of over
From a scientific perspective, the ability of edited hematopoietic stem and progenitor cells (HSPCs) to engraft efficiently in murine models and maintain clinically relevant correction levels suggests robust and durable treatment potential. If these results can be replicated in human clinical trials, it could revolutionize the treatment landscape for SCD and potentially other genetic disorders caused by point mutations.
Overall, this development positions Cellectis as a leader in the gene therapy space, with promising implications for the future of genetic medicine.
The publication of Cellectis' non-viral gene therapy approach for sickle cell disease could have significant market implications. Sickle cell disease is a prevalent hereditary condition that represents a substantial unmet medical need. Current treatment options are limited and often come with considerable side effects, making new therapies highly desirable.
Cellectis' innovative use of TALEN® technology and non-viral delivery methods positions the company at the forefront of gene editing advancements. This could attract considerable interest from investors and larger pharmaceutical companies looking for strategic partnerships or acquisitions, given the potential market size and impact.
The achievement of high gene correction efficiencies and the ability to rescue functional hemoglobin expression highlight the commercial viability of this therapy. If successful in clinical trials, the therapy could capture a significant market share, driving revenue growth and enhancing Cellectis' market position.
This development also underscores the broader trend towards precision medicine and the growing investment in gene therapies, providing a strong case for sustained investor interest in the biotechnology sector.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease.
Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point mutation in the HBB gene, which encodes the β subunit of hemoglobin (Hb). Normally, red blood cells adopt a disc-like shape that allows them to move easily through the blood vessels and deliver oxygen throughout the body. In sickle cell disease, red blood cells become crescent or “sickle”-shaped, a dysfunctional state that impairs blood flow, oxygen delivery and triggers multiple debilitating symptoms including intense pain crisis.
Cellectis leverages TALEN® technology and a non-viral gene repair template delivery to develop a clinically relevant gene editing process in hematopoietic stem and progenitor cells (HSPCs). This process enables efficient HBB gene correction with high precision, specificity and minimal genomic adverse events.
Applying this HBB gene correction process to SCD patient-HSPCs results in over
“The unique combination of TALEN® technology, non-viral DNA repair template design and Cellectis’ PulseAgile proprietary electroporation system enabled us to set up a precise, efficient and clinically relevant HBB gene correction process in long term hematopoietic stem and progenitor cells from SCD patients” said Julien Valton, Ph.D., Vice President Gene Therapy at Cellectis. “SCD is a devastating blood disorder affecting millions of individuals worldwide. The TALEN® gene therapy approach could represent a new alternative treatment, especially for patients with limited therapeutic options. This gene editing process bears a strong therapeutic potential as it could be easily used to correct point mutations associated to many other genetic diseases.”
Research data showed that:
- TALEN® technology, coupled to non-viral DNA correction template delivery, achieves high HBB gene correction efficiencies in healthy donor - and SCD patient - HSPCs in vitro.
- HBB gene correction translates into an efficient rescue of functional Adult Hemoglobin (HbA) and a significant decrease of dysfunctional Sickle Hemoglobin (HbS) and Sickle red blood cells.
- TALEN® nuclease activity is highly specific with only one off-target site detected at the HBD locus.
- Corrected HSPCs display long-term in vivo engraftment capacity in murine animal model, indicating their strong potential for therapeutic applications towards SCD.
The article is available on Nature Communications website by clicking on this link:
https://doi.org/10.1038/s41467-024-49353-3
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
Forward-looking Statements
This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “could,” and “potential,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, include statements about the potential benefit and potential development of the Company’s research and development programs. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
FAQ
What is Cellectis's new approach for treating Sickle Cell Disease?
What results were achieved with Cellectis's gene therapy for Sickle Cell Disease?
When was the breakthrough in gene therapy announced by Cellectis?
What technology does Cellectis use for its gene therapy for Sickle Cell Disease?
What are the potential applications of Cellectis's gene therapy beyond Sickle Cell Disease?
What did preclinical data reveal about Cellectis's gene therapy?
